News & Events

June 25, 2013

IntegriChain Announces Completion of New NDA Benchmark Report on Pharmacy in Stock Rates

THE DNA BENCHMARK REPORT DETAILS HOW OFTEN A PHARMACEUTICAL PRODUCT IS IN STOCK IN A RETAIL PHARMACY WITH STATISTICS BROKEN DOWN BY FAST AND SLOW MOVING THERAPIES, AS WELL AS BY THERAPEUTIC CATEGORY.

Princeton, NJ – June 25, 2013 – IntegriChain, Inc., the developer of Demand Network Analytics (DNA) commerce platform, announced today the completion of a new DNA Benchmark Report on pharmacy in stock rates.

The DNA Benchmark Report: Pharmacy In Stock Rates, was built around pharmaceutical distribution data processed in the DNA commerce optimization cloud. This report includes statistics for nine of the largest and fastest growing prescription therapeutic categories that are distributed through the retail pharmacy channel, including pain management, diabetes, and HIV.

As highlighted in the report, pharmacy in stock rates are far lower than many in the industry have historically assumed. On any given day, even the fastest moving brand pharmaceuticals are in stock at less than 70% of retail pharmacies. Slow moving, expensive, or scheduled therapies may be in stock at as few as 20% to 30% of retail pharmacies.

Josh Halpern, IntegriChain Executive Vice President, stated, “Pharmacy shelf space is limited, and the patent cliff is challenging the amount of space available for the long tail of branded therapies. Our report highlights the need for branded pharmaceutical manufacturers and their trade partners to deepen their collaboration in order to ensure efficient product availability in a post-patent cliff environment.”

IntegriChain presented the Benchmark Report to pharmaceutical suppliers and distributors at the HDMA Business & Leadership Conference in Orlando this June. A full version of the report will be available at the 5th Annual DNA Innovation Summit this September in Washington, DC.

Please contact Ally Hanlon at DNA@integrichain.com for additional information about DNA Benchmark Reports or to request a presentation of the report’s findings.

About IntegriChain
IntegriChain launched the Demand Network Analytics (DNA) commerce optimization cloud in 2007. Today, DNA is helping a growing community of innovative manufacturers realize their vision of a collaborative, cost efficient, and demand driven distribution channel. DNA’s demand visibility suite and informed applications optimize hundreds of billions of dollars in annual commerce, helping suppliers lower their distribution costs, improve sales predictability, and ensure product availability throughout their distribution channels. For more information, please visit www.integrichain.com.

###

All names referred to are trademarks or registered trademarks of their respective owners.

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand